Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: irasia.com
$12.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Mesoblast Ltd reports positive type 2 diabetes trial results


Tuesday, 3 Dec 2013 06:36pm EST 

Mesoblast Ltd:Says topline results from the phase 2 trial of its Mesenchymal Precursor Cells (MPCs) in subjects with type 2 diabetes.Says the results of the trial support the safety and tolerability of a single intravenous infusion of MPCs in type 2 diabetes.Says additionally, there was an improvement in glycemic control as evidenced by reduction in hemoglobin A1c (HbA1c).Says the Phase 2 randomized, single-blind, placebo-controlled, dose escalation trial was conducted across 18 sites in the United States.Says the trial evaluated the effects of a single intravenous infusion of 0.3, 1.0 or 2.0 million MPCs/kg or placebo over 12 weeks in 61 patients with a mean diabetes duration of 10 years.Says the MPCs were safe and well tolerated with no treatment-related adverse events, meeting the trial's primary endpoint.Says following a single intravenous MPC infusion, overall HbA1c levels were reduced over the 12-week study period when compared to placebo. 

Company Quote

4.44
0.39 +9.63%
19 Dec 2014